1.
Gooderham M, Spelman L, Imafuku S, Romanelli M, Merola JF, Armstrong AW, Colston E, Banerjee S, Scharnitz T, Blauvelt A. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin [Internet]. 2023Jul.17 [cited 2024Jul.16];7(4):s219. Available from: https://jofskin.org/index.php/skin/article/view/2225